Henri Timmers has been appointed professor of Internal Medicine, with a special focus on endocrine diseases, at Radboud University/Radboud university medical center. This appointment became effective on 1 May 2020.
Professor Timmers is an expert in the field of hormonal diseases, such as diseases of the adrenal, thyroid and pituitary glands, and gonads. Tumours of the adrenal gland are his particular research focus. Timmers: “Although they are usually benign, they can lead to severe organ damage through overproduction of adrenal hormones such as adrenaline, cortisol and aldosterone.” His work ranges from laboratory research and new treatment methods to clinical trials with patients. This all occurs within a context of international cooperation because of the rarity of some of these diseases.
Henri Timmers (Veghel, 1971) graduated as MD (cum laude) at Radboud University in 1997. In 2004 he received his PhD from this university (also cum laude) for research into the effects of neck surgery and radiation on the autonomic nervous system.
In 2006 he became an internist-endocrinologist at the Radboud university medical center and in 2017 he was appointed associate professor of Adrenal Diseases. From 2006 to 2008, he worked as a postdoctoral researcher at the National Institutes of Health, Bethesda, USA.
Professor Timmers is a board member of the European Network for the Study of Adrenal Tumors (www.ensat.org).
Related news items
Jong KNCV organizes a Pitch competition for PhD candidates13 August 2020
Are you a PhD candidate and would you like to win 500 euros with a pitch about your research? Young KNCV gives you that chance! During the KNCV Chemistry 2020 Evening on October 8th.read more
Collective invasion induced by autocrine purinergic loop through connexin-43 hemichannels13 August 2020
Peter Friedl and Paul Span show in Journal of Cell Biology that breastcancer cells release purines into the extracellular space via connexin-43 hemichannels to control collective invasion.read more
TP53 allelic state is critical for diagnostic and prognostic precision in blood cancer12 August 2020
An international study, in which Joop Jansen participated, shows that a double mutaton in TP53 gene deteriotes the prognosis of a rare form of blood cancer. If there is only one mutation or no mutation, then the prognosis is better.read more
BCG vaccine is safe with no increased risk of COVID-19 symptoms says Mihai Netea11 August 2020
The BCG vaccine has a general stimulatory effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.read more
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more